Skip to main content

Table 4 Representative drugs targeting Wnt signaling in clinical trials

From: The Wnt signaling pathway in tumorigenesis, pharmacological targets, and drug development for cancer therapy

Drug name Target Type of cancer Phase Therapeutic programe NCT number
CWP232291 beta-catenin acute myeloid leukemia,
chronic myelomonocytic leukemia
phase 1 single group assignment NCT01398462
Sinecatechins beta-catenin superficial basal cell carcinoma phase 2/3 parallel assignment NCT02029352
Foxy-5 Wnt-5a metastatic breast cancer,
colorectal cancer,
prostate cancer
phase 1 single group assignment NCT02020291
Foxy-5 Wnt-5a metastatic breast cancer,
metastatic colon cancer,
metastatic prostate cancer
phase 1 single group assignment NCT02655952
Rosmantuzumab (OMP-131R10) Wnt/beta-catenin metastatic colorectal cancer phase 1 single group assignment. OMP-131R10 as a single agent and in combination with FOLFIRI NCT02482441
PRI-724 Wnt/beta-catenin acute myeloid leukemia,
chronic myeloid leukemia
phase 1/2 parallel assignment NCT01606579
PRI-724 Wnt/beta-catenin pancreatic cancer phase 1 all enrolled subjects will be treated with both PRI-724 and gemcitabine NCT01764477
Onc201 Wnt/beta-catenin advanced solid tumors,
multiple myeloma
phase 1 single group assignment NCT02609230
Mesalazine Wnt/beta-catenin sporadic colorectal adenoma phase 2 parallel assignment NCT01894685
Resveratrol Wnt colon cancer phase 1 single group assignment NCT00256334
Diclofenac Wnt basal cell carcinoma phase 2 topical vitamin D3, diclofenac or a combination of both NCT01358045
Genistein Wnt colon cancer,
rectal cancer,
colorectal cancer
phase 1/2 Genistein combined with FOLFOX or FOLFOX-Avastin NCT01985763
Ipafricept
(OMP-54F28)
Wnt sarcomas,
basal cell carcinoma,
ovarian cancer,
desmoid tumors and prostate cancer
phase 1 after OMP-54F28 is discontinued, all subjects will receive vitamin D3 and calcium carbonate twice daily NCT01608867
WNT974 (LGK974) RNF43 metastatic colorectal cancer phase 1/2 phase l: dose escalation phase;
phase ll: single group assessing the triple combination of WNT974, LGX818 and cetuximab
NCT02278133
ETC-1922159 Porcupine advanced solid tumors phase 1 ETC-1922159 as a single agent and in combination with pembrolizumab NCT02521844
BI 905677 LRP5/6 different types of advanced cancer phase 1 sequential assignment NCT03604445
LY2090314 GSK-3β advanced or metastatic cancer phase 1 LY2090314 in combination with pemetrexed and carboplatin NCT01287520
LY2090314 GSK-3β leukemia phase 2 single group assignment NCT01214603
Vantictumab (OMP-18R5) FZD stage IV pancreatic cancer phase 1 single group assignment, vantictumab in combination with nab-paclitaxel and gemcitabine NCT02005315
Vantictumab (OMP-18R5) FZD non-small cell lung cancer phase 1 single group assignment, vantictumab in combination with docetaxel NCT01957007
Vantictumab (OMP-18R5) FZD metastatic breast cancer phase 1 single group assignment, Vantictumab in combination with paclitaxel NCT01973309
Niclosamide Frizzled prostate carcinoma phase 1 niclosamide in combination with enzalutamide NCT02532114
BHQ880 DKK-1 multiple myeloma phase 2 parallel assignment, BHQ880 in combination with bortezomib and dexamethasone NCT01337752
DKN-01 DKK-1 carcinoma of intrahepatic
and extra-hepatic biliary system, carcinoma of gallbladder
phase 1 parallel assignment, DKN-01 in combination with gemcitabine and cisplatin NCT02375880
Bortezomib DKK-1 multiple myeloma phase 4 prospective NCT01026701
PRI-724 CBP/beta-catenin pancreatic cancer phase 1 single group assignment NCT01764477
PRI-724 CBP/beta-catenin myeloid malignancies phase 1/2 parallel assignment, PRI-724 as a single agent and in combination with low dose ara-C therapy or dasatinib NCT01606579